(Q46351516)

21 December 2017

title

High bone turnover but normal bone mineral density in women suffering from schizophrenia (English)

1 reference

21 December 2017

0 references

N Bergemann

1

1 reference

21 December 2017

P Parzer

series ordinal

2

1 reference

21 December 2017

C Mundt

series ordinal

3

1 reference

21 December 2017

B Auler

series ordinal

4

1 reference

21 December 2017

language of work or name

English

0 references

publication date

26 March 2008

1 reference

21 December 2017

published in

Psychological Medicine

1 reference

21 December 2017

volume

38

1 reference

21 December 2017

issue

8

1 reference

21 December 2017

page(s)

1195-1201

1 reference

21 December 2017

Parathyroid hormone - a bone anabolic and catabolic agent

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Prolactin and antipsychotic medications: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Calcium Metabolism in Schizophrenic Patients on Long-Term Neuroleptic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Bone mineral density and prolactin associations in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Hyperprolactinaemia and antipsychotic therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Decreased bone mineral density in medicated psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Effect of carbamazepine and valproate on bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Effect of antiepileptic drugs on bone density in ambulatory patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Bone disorder in men with chronic alcoholism: a reversible disease?

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Osteoporosis and schizophrenia: can we limit known risk factors?

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Basic science and clinical utility of biochemical markers of bone turnover--a Congress report

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Certain neuroleptics reduce bone mineralization in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Constitutional factors, stature, and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

https://api.crossref.org/works/10.1017%2FS003329170800319X

1 reference

7 January 2021

Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Neuroleptics and bone mineral density

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Neuroleptics, prolactin, and osteoporosis

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

Cigarettes and the skeleton

1 reference

https://api.crossref.org/works/10.1017%2FS003329170800319X

7 January 2021

10.1017/S003329170800319X

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017